Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen

Key Points

• Lucid Diagnostics was upgraded from a "sell" to a "hold" rating by analysts at Wall Street Zen, while five analysts have rated the stock with a "buy" rating.
• The stock currently has a price target consensus of $3.65 per share, reflecting optimism among analysts despite its recent trading low of $0.75.
• Insider trading activity includes Director Dennis Matheis purchasing 100,000 shares at $1.02 each, marking a significant increase in their ownership by 17.69%.

Lucid Diagnostics (NASDAQ:LUCD - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday.

Several other equities research analysts have also issued reports on LUCD. Needham & Company LLC reaffirmed a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Wednesday, August 13th. BTIG Research lifted their price target on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a "buy" rating in a report on Friday, September 5th. Finally, Ascendiant Capital Markets lifted their price target on shares of Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a report on Friday, June 6th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $3.65.

Lucid Diagnostics Stock Down 1.0%

LUCD stock opened at $1.03 on Friday. Lucid Diagnostics has a 12 month low of $0.75 and a 12 month high of $1.80. The firm has a market cap of $137.48 million, a P/E ratio of -0.87 and a beta of 1.24. The company's 50-day moving average price is $1.09 and its two-hundred day moving average price is $1.23.

Insider Buying and Selling

In other Lucid Diagnostics news, Director Dennis Matheis purchased 100,000 shares of the firm's stock in a transaction on Wednesday, August 20th. The stock was acquired at an average price of $1.02 per share, for a total transaction of $102,000.00. Following the purchase, the director owned 665,443 shares of the company's stock, valued at $678,751.86. This trade represents a 17.69% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 6.80% of the company's stock.

Hedge Funds Weigh In On Lucid Diagnostics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Berkshire Asset Management LLC PA purchased a new position in shares of Lucid Diagnostics during the first quarter worth approximately $30,000. Goldman Sachs Group Inc. boosted its holdings in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company's stock valued at $129,000 after acquiring an additional 22,727 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Lucid Diagnostics during the 1st quarter valued at $37,000. Quadrature Capital Ltd purchased a new position in shares of Lucid Diagnostics in the 2nd quarter worth about $29,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Lucid Diagnostics in the 1st quarter worth about $39,000. Institutional investors own 74.01% of the company's stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.